

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 November 2021 (18.11.2021)



(10) International Publication Number
WO 2021/231208 A1

(51) International Patent Classification:

A61K 31/56 (2006.01) A61K 31/675 (2006.01)
A61K 45/06 (2006.01) A61K 39/42 (2006.01)
A61P 31/14 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/031282

(22) International Filing Date:

07 May 2021 (07.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/022,479 09 May 2020 (09.05.2020) US
63/053,056 17 July 2020 (17.07.2020) US

(71) Applicant: REATA PHARMACEUTICALS, INC.

[US/US]; 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US).

(72) Inventors: FERGUSON, Deborah; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). WIGLEY, W., Christian; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). MEYER, Colin; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). HUFF, J., Warren; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). KRAL, Robert M., Jr.; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US).

(74) Agent: SCHNEPP, Amanda, S.J.; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF

(57) Abstract: The present invention provides methods of treating patients infected with a coronavirus. In particular, provided are methods of treating or preventing COVID-19, or symptoms or complications thereof, in patients in need thereof using bardoxolone methyl or analogs thereof, and/or preventing the onset of COVID-19 in patients infected with SARS-CoV-2.



WO 2021/231208 A1